There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Shanna Trenaman |
| Institution: | Dalhousie University |
| Department: | Medicine |
| Country: | |
| Proposed Analysis: | Understanding the relationship between sex, frailty, anticholinergic medication exposure and dementia As our mechanistic understanding of dementia progresses it becomes clear that sex, frailty and anticholinergic medication exposure all play an unclear role in progression to dementia. Recently published data has identified that anticholinergic medication exposure increases mild cognitive impairment and this is further increased when genetic or biomarker risk factors are included (Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L; Alzheimer's Disease Neuroimaging Initiative. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020 Oct 20;95(16):e2295-e2304. doi: 10.1212/WNL.0000000000010643. Epub 2020 Sep 2. PMID: 32878992; PMCID: PMC7713781. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713781/pdf/NEUROLOGY2019020982.pdf). We know that sex and frailty also are related to dementia (Canevelli M, Arisi I, Bacigalupo I, Arighi A, Galimberti D, Vanacore N, D'Onofrio M, Cesari M, Bruno G; Alzheimer’s Disease Neuroimaging Initiative. Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. Geroscience. 2021 Apr;43(2):1039-1051. doi: 10.1007/s11357-020-00293-y. Epub 2020 Nov 19. PMID: 33210215; PMCID: PMC8110661. https://pubmed.ncbi.nlm.nih.gov/33210215/) but their relationship with anticholinergic medication exposure as risk factors for dementia has not been explored. We propose to use the ADNI dataset to explore the relationships between sex, frailty and anticholinergic medication exposure with dementia. This may help explain risk from a multi-contributor set of factors (sex, frailty, biomarkers, exposure, genetics) and what characteristics allows us to resist those risk factors. The objective is to examine how anticholinergic medication exposure moderates dementia risk with consideration of sex and frailty. |
| Additional Investigators | |
| Investigator's Name: | Melissa Andrew |
| Proposed Analysis: | Understanding the relationship between sex, frailty, anticholinergic medication exposure and dementia As our mechanistic understanding of dementia progresses it becomes clear that sex, frailty and anticholinergic medication exposure all play an unclear role in progression to dementia. Recently published data has identified that anticholinergic medication exposure increases mild cognitive impairment and this is further increased when genetic or biomarker risk factors are included (Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L; Alzheimer's Disease Neuroimaging Initiative. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020 Oct 20;95(16):e2295-e2304. doi: 10.1212/WNL.0000000000010643. Epub 2020 Sep 2. PMID: 32878992; PMCID: PMC7713781. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713781/pdf/NEUROLOGY2019020982.pdf). We know that sex and frailty also are related to dementia (Canevelli M, Arisi I, Bacigalupo I, Arighi A, Galimberti D, Vanacore N, D'Onofrio M, Cesari M, Bruno G; Alzheimer’s Disease Neuroimaging Initiative. Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. Geroscience. 2021 Apr;43(2):1039-1051. doi: 10.1007/s11357-020-00293-y. Epub 2020 Nov 19. PMID: 33210215; PMCID: PMC8110661. https://pubmed.ncbi.nlm.nih.gov/33210215/) but their relationship with anticholinergic medication exposure as risk factors for dementia has not been explored. We propose to use the ADNI dataset to explore the relationships between sex, frailty and anticholinergic medication exposure with dementia. This may help explain risk from a multi-contributor set of factors (sex, frailty, biomarkers, exposure, genetics) and what characteristics allows us to resist those risk factors. The objective is to examine how anticholinergic medication exposure moderates dementia risk with consideration of sex and frailty. |
| Investigator's Name: | Kenneth Rockwood |
| Proposed Analysis: | Understanding the relationship between sex, frailty, anticholinergic medication exposure and dementia As our mechanistic understanding of dementia progresses it becomes clear that sex, frailty and anticholinergic medication exposure all play an unclear role in progression to dementia. Recently published data has identified that anticholinergic medication exposure increases mild cognitive impairment and this is further increased when genetic or biomarker risk factors are included (Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L; Alzheimer's Disease Neuroimaging Initiative. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020 Oct 20;95(16):e2295-e2304. doi: 10.1212/WNL.0000000000010643. Epub 2020 Sep 2. PMID: 32878992; PMCID: PMC7713781. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713781/pdf/NEUROLOGY2019020982.pdf). We know that sex and frailty also are related to dementia (Canevelli M, Arisi I, Bacigalupo I, Arighi A, Galimberti D, Vanacore N, D'Onofrio M, Cesari M, Bruno G; Alzheimer’s Disease Neuroimaging Initiative. Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. Geroscience. 2021 Apr;43(2):1039-1051. doi: 10.1007/s11357-020-00293-y. Epub 2020 Nov 19. PMID: 33210215; PMCID: PMC8110661. https://pubmed.ncbi.nlm.nih.gov/33210215/) but their relationship with anticholinergic medication exposure as risk factors for dementia has not been explored. We propose to use the ADNI dataset to explore the relationships between sex, frailty and anticholinergic medication exposure with dementia. This may help explain risk from a multi-contributor set of factors (sex, frailty, biomarkers, exposure, genetics) and what characteristics allows us to resist those risk factors. The objective is to examine how anticholinergic medication exposure moderates dementia risk with consideration of sex and frailty. |
| Investigator's Name: | Pilar Robinson Gonzalez |
| Proposed Analysis: | To look at the relationship between frailty, anticholinergic burden, sex/gender and clinical dementia |
| Investigator's Name: | Lucy Eum |
| Proposed Analysis: | To investigate the relationship between frailty, anticholinergic burden, sex/gender and dementia-related neuropathology. |
